Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
March 21, 2024 16:15 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
March 07, 2024 16:10 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an...
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
August 07, 2023 08:30 ET
|
Evoke Pharma, Inc.
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize...
Evoke Pharma Reports First Quarter 2023 Financial Results
May 15, 2023 16:05 ET
|
Evoke Pharma, Inc.
Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE...
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
March 23, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
March 21, 2023 16:05 ET
|
Evoke Pharma, Inc.
Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 ...
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
February 21, 2023 07:00 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
December 07, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®
November 30, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Record Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET
|
Evoke Pharma, Inc.
80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 ...